Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.

ABSTRACT:

Background

In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea.

Methods

In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the

SUBMITTER: van Griensven J 

PROVIDER: S-EPMC5856332 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature